The BioXmark liquid fiducial markers are being evaluated for their feasibility and accuracy in enhancing image-guided radiotherapy for rectal cancer. The trial, sponsored by Maastricht Radiation Oncology, involves a small cohort of 20 patients and aims to establish the markers' positional stability and visibility during treatment. If successful, this technology could improve treatment precision in rectal cancer, potentially leading to broader adoption in clinical practice. The market for rectal cancer therapies is significant, with increasing demand for innovative solutions that enhance treatment outcomes. Competitive implications include the potential for BioXmark to differentiate itself in a crowded oncology market, particularly if it demonstrates superior efficacy in guiding radiotherapy. Diligence considerations should focus on the regulatory pathway for the device and any existing competition in the fiducial marker space.